Effect of PPAR-gamma agonists on macrophage activation in type2 diabetes mellitus

Basit Öğe Kaydı
dc.contributor.authorSozmen, Bulent
dc.contributor.authorKarakas, Emel Yigit
dc.contributor.authorTopcugil, Fusun
dc.contributor.authorAltiner, Nazif
dc.contributor.authorSozmen, Eser Y.
dc.date.accessioned2019-10-27T10:04:42Z
dc.date.available2019-10-27T10:04:42Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractAim: Recently, it has been proposed that inflammation triggered by macrophages as the pathogenic mechanism linked to the development of obesity-related insulin resistance. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists which increase the insulin receptor sensitivity. might improve glycemic control by enhancing insulin sensitivity and ameliorate the impaired lipid profile. In this study, we assessed the effect of rosiglitazone (PPAR-gamma agonist) on the insulin resistance and inflammatory markers. Material and Method: Thirty patients (11 men. 19 women) with type II diabetes mellitus (DM) were taken into the study. They were treated by rosiglitazone in a dose of 4mg/day as well as a diet for 12 weeks. Results: Rosiglitazone treatment significantly decreased HbA1c (p<0,01), IR-HOMA, hsCRP (p<0,01), triglyceride levels (p<0,05), CETP activity (p<0,01) and basal serum oxidation (TBARS levels, p<0,05). However, Chitotriosidase activity significantly increased after Rosiglitazone treatment (p<0,01). TNF, IL-6, sTNFR1, and sTNFR2 levels showed no statistically significant difference compared to their basal levels. Discussion: Rosiglitazone might treat diabetes by mediating glucose/lipid metabolism and preventing lipid oxidation in patients with DM. On the other hand, it has a dual role on inflammation; while it might induce macrophage activation suggesting its pro-inflammatory effect, It might also reduce the CRP levels by lowering gene expression suggesting its anti-inflammatory effect.en_US
dc.identifier.doi10.4328/JCAM.5622
dc.identifier.endpage277en_US
dc.identifier.issn1309-0720
dc.identifier.issn1309-2014
dc.identifier.issn1309-0720en_US
dc.identifier.issn1309-2014en_US
dc.identifier.issue4en_US
dc.identifier.startpage273en_US
dc.identifier.urihttps://doi.org/10.4328/JCAM.5622
dc.identifier.urihttps://hdl.handle.net/11454/30270
dc.identifier.volume9en_US
dc.identifier.wosWOS:000435650500003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherDerman Medical Publen_US
dc.relation.ispartofJournal of Clinical and Analytical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInsulin Resistanceen_US
dc.subjectChitotriosidaseen_US
dc.subjectPPAR-Gammaen_US
dc.subjectTNFen_US
dc.titleEffect of PPAR-gamma agonists on macrophage activation in type2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu